PMID- 38192627
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240110
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Autophagy-mediated nanomaterials for tumor therapy.
PG  - 1194524
LID - 10.3389/fonc.2023.1194524 [doi]
LID - 1194524
AB  - Autophagy is a lysosomal self-degradation pathway that plays an important 
      protective role in maintaining intracellular environment. Deregulation of 
      autophagy is related to several diseases, including cancer, infection, 
      neurodegeneration, aging, and heart disease. In this review, we will summarize 
      recent advances in autophagy-mediated nanomaterials for tumor therapy. Firstly, 
      the autophagy signaling pathway for tumor therapy will be reviewed, including 
      oxidative stress, mammalian target of rapamycin (mTOR) signaling and 
      autophagy-associated genes pathway. Based on that, many autophagy-mediated 
      nanomaterials have been developed and applied in tumor therapy. According to the 
      different structure of nanomaterials, we will review and evaluate these 
      autophagy-mediated nanomaterials' therapeutic efficacy and potential clinical 
      application.
CI  - Copyright (c) 2023 Liao, Liu, Fan, Sun, Zhang and Wu.
FAU - Liao, Zijian
AU  - Liao Z
AD  - State Key Laboratory of Targeting Oncology, National Center for International 
      Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting 
      Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and 
      Therapy, Guangxi Medical University, Nanning, Guangxi, China.
FAU - Liu, Xiyu
AU  - Liu X
AD  - State Key Laboratory of Targeting Oncology, National Center for International 
      Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting 
      Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and 
      Therapy, Guangxi Medical University, Nanning, Guangxi, China.
FAU - Fan, Dianfa
AU  - Fan D
AD  - State Key Laboratory of Targeting Oncology, National Center for International 
      Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting 
      Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and 
      Therapy, Guangxi Medical University, Nanning, Guangxi, China.
FAU - Sun, Xingjun
AU  - Sun X
AD  - State Key Laboratory of Targeting Oncology, National Center for International 
      Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting 
      Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and 
      Therapy, Guangxi Medical University, Nanning, Guangxi, China.
FAU - Zhang, Zhikun
AU  - Zhang Z
AD  - State Key Laboratory of Targeting Oncology, National Center for International 
      Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting 
      Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and 
      Therapy, Guangxi Medical University, Nanning, Guangxi, China.
FAU - Wu, Pan
AU  - Wu P
AD  - State Key Laboratory of Targeting Oncology, National Center for International 
      Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting 
      Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and 
      Therapy, Guangxi Medical University, Nanning, Guangxi, China.
AD  - School of Pharmacy, Guangxi Medical University, Nanning, Guangxi, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231215
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10773885
OTO - NOTNLM
OT  - apoptosis
OT  - autophagy
OT  - nanomaterials
OT  - signaling pathway
OT  - tumor therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/09 06:41
MHDA- 2024/01/09 06:42
PMCR- 2023/01/01
CRDT- 2024/01/09 03:54
PHST- 2023/03/27 00:00 [received]
PHST- 2023/06/30 00:00 [accepted]
PHST- 2024/01/09 06:42 [medline]
PHST- 2024/01/09 06:41 [pubmed]
PHST- 2024/01/09 03:54 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1194524 [doi]
PST - epublish
SO  - Front Oncol. 2023 Dec 15;13:1194524. doi: 10.3389/fonc.2023.1194524. eCollection 
      2023.